Literature DB >> 15152038

Castration restores function and neurofilament alterations of aged symptomatic males in a transgenic mouse model of spinal and bulbar muscular atrophy.

Erica S Chevalier-Larsen1, Christopher J O'Brien, Huiyi Wang, Shannon C Jenkins, Latia Holder, Andrew P Lieberman, Diane E Merry.   

Abstract

Transgenic models of neurodegenerative disease have proved uniquely powerful for delineating pathways of neuronal dysfunction and cell death. We have developed a transgenic model of the polyglutamine disease spinal and bulbar muscular atrophy (SBMA), an adult-onset, slowly progressive motor neuron disease caused by polyglutamine expansion in the androgen receptor (AR). Mice bearing a human AR with 112 glutamines reproduce many aspects of SBMA, including slowly progressive, gender-specific motor deficits, and neuronal intranuclear inclusions. Despite substantial motor deficits in male AR112Q mice, no motor neuron loss was observed, indicating that neuronal dysfunction, rather than neuronal death, is central to disease. Moreover, reduced levels of unphosphorylated neurofilament heavy chain (NF-H) were observed in motor neurons, suggesting a role for NF-H in SBMA neuronal dysfunction. The elimination of androgens by surgical castration of severely affected, aged 112Q male mice partially restored motor function as well as NF-H levels. These data suggest that hormone-based therapies designed to treat SBMA patients, even with advanced disease, are likely to be effective.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15152038      PMCID: PMC6729468          DOI: 10.1523/JNEUROSCI.0808-04.2004

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  99 in total

Review 1.  Developing treatment for spinal and bulbar muscular atrophy.

Authors:  Kenneth H Fischbeck
Journal:  Prog Neurobiol       Date:  2012-06-02       Impact factor: 11.685

2.  SIRT1 modulates aggregation and toxicity through deacetylation of the androgen receptor in cell models of SBMA.

Authors:  Heather L Montie; Richard G Pestell; Diane E Merry
Journal:  J Neurosci       Date:  2011-11-30       Impact factor: 6.167

3.  Native functions of the androgen receptor are essential to pathogenesis in a Drosophila model of spinobulbar muscular atrophy.

Authors:  Natalia B Nedelsky; Maria Pennuto; Rebecca B Smith; Isabella Palazzolo; Jennifer Moore; Zhiping Nie; Geoffrey Neale; J Paul Taylor
Journal:  Neuron       Date:  2010-09-23       Impact factor: 17.173

Review 4.  Therapeutic approaches to spinal and bulbar muscular atrophy.

Authors:  Srikanth Ranganathan; Kenneth H Fischbeck
Journal:  Trends Pharmacol Sci       Date:  2010-09-20       Impact factor: 14.819

5.  Difference in chronological changes of outcome measures between untreated and placebo-treated patients of spinal and bulbar muscular atrophy.

Authors:  Atsushi Hashizume; Masahisa Katsuno; Haruhiko Banno; Keisuke Suzuki; Noriaki Suga; Fumiaki Tanaka; Gen Sobue
Journal:  J Neurol       Date:  2011-09-28       Impact factor: 4.849

Review 6.  Onset Manifestations of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease).

Authors:  Josef Finsterer; Gianni Soraru
Journal:  J Mol Neurosci       Date:  2015-10-19       Impact factor: 3.444

Review 7.  Pathogenic mechanisms and therapeutic strategies in spinobulbar muscular atrophy.

Authors:  Jason P Chua; Andrew P Lieberman
Journal:  CNS Neurol Disord Drug Targets       Date:  2013-12       Impact factor: 4.388

Review 8.  Pathogenic mechanisms of a polyglutamine-mediated neurodegenerative disease, spinocerebellar ataxia type 1.

Authors:  Huda Y Zoghbi; Harry T Orr
Journal:  J Biol Chem       Date:  2008-10-28       Impact factor: 5.157

9.  Overexpression of wild-type androgen receptor in muscle recapitulates polyglutamine disease.

Authors:  Douglas Ashley Monks; Jamie A Johansen; Kaiguo Mo; Pengcheng Rao; Bryn Eagleson; Zhigang Yu; Andrew P Lieberman; S Marc Breedlove; Cynthia L Jordan
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-02       Impact factor: 11.205

10.  The androgen receptor's CAG/glutamine tract in mouse models of neurological disease and cancer.

Authors:  Andrew P Lieberman; Diane M Robins
Journal:  J Alzheimers Dis       Date:  2008-06       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.